Published in final edited form as:

J Mol Cell Cardiol. 2007 November ; 43(5): 545–551. doi:10.1016/j.yjmcc.2007.08.014.

Adenosine A₁ Receptor Mediates Delayed Cardioprotective Effect of Sildenafil in Mouse

Fadi N. Salloum, Anindita Das, Christopher S. Thomas, Chang Yin, and Rakesh C. Kukreja

Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298-0281, USA

Abstract

Sildenafil induces powerful cardioprotection against ischemia/reperfusion (I/R) injury. Since adenosine is known to be major trigger of ischemic preconditioning, we hypothesized that A₁ adenosine receptor (A₁AR) activation plays a role in sildenafil-induced cardioprotective signaling. Adult male C57BL-wild type (WT) mice or their corresponding A₁AR knockout (A₁AR-KO) mice were treated intraperitoneally (*i.p.*) with either sildenafil (0.71 mg/kg, equivalent to 50 mg dose for a 70 kg patient) or volume-matched saline. The selective A₁AR antagonist 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX; 0.1 mg/kg, *i.p.*) was administered 30 min before sildenafil. The hearts were isolated 24 hours later and subjected to 30 min of global ischemia and 1 hr of reperfusion in Langendorff mode. Post-ischemic myocardial infarct size (mean±SEM; % of risk area) was reduced in C57BL-WT mice treated with sildenafil (5.6±0.9) versus saline control group (27.3±2.1; *P*<0.05; *n*=6/each). However, sildenafil failed to protect the A₁AR-KO hearts (31.6±1.9 vs. 32.3±1.5 with saline, *p*>0.05). Additionally, DPCPX treatment abolished the infarct limiting effect of sildenafil (27.3±3.2, *p*<0.05). DPCPX alone had no effect on infarct size as compared with the control group. No significant changes in post-ischemic recovery of left ventricular pressure and heart rate were observed in the sildenafil-treated group. We further examined the effect of sildenafil in protection against simulated ischemia and reoxygenation injury in adult cardiomyocytes derived from WT and A₁AR-KO mice. WT myocytes treated with sildenafil (1μM) demonstrated significantly lower trypan blue-positive necrotic cells. However, cardiomyocytes derived from A₁AR-KO mice or DPCPX-treated WT cells failed to show protection against necrosis with sildenafil. These results suggest that A₁AR activation following treatment with sildenafil plays an integral role in the signaling cascade responsible for delayed protection against global I/R injury.

© 2007 Elsevier Ltd. All rights reserved.

Address for Correspondence: Rakesh C Kukreja, PhD Professor of Medicine, Physiology, Biochemistry and Emergency Medicine Eric Lipman Professor of Cardiology Division of Cardiology, Box 980281 Virginia Commonwealth University 1101 East Marshall Street, Room 7-046 Richmond, VA 23298, USA Telephone: (804) 828-0389 Fax: (804) 828-8700 rakesh@hsc.vcu.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

Phosphodiesterase inhibitors; Myocardial preconditioning; Ischemia-reperfusion injury; cGMP; Adenosine; Adenosine A₁ receptor; Infarct size

Introduction

Phosphodiesterase-5 (PDE-5) inhibitors including sildenafil, vardenafil and tadalafil are a class of drugs that have been developed for treatment of erectile dysfunction (ED) (1) and more recently for pulmonary artery hypertension (2). We first showed that sildenafil induced preconditioning-like protective effects against ischemia/reperfusion (I/R) injury in the rabbit (3) and mouse heart (4). Moreover, sildenafil attenuated necrosis as well as apoptosis in adult cardiomyocytes subjected to simulated ischemia/reoxygenation (SI/RO) (5). A series of studies from our laboratory further showed that activation of protein kinase C (6), phosphorylation of extracellular-signal-regulated kinase (ERK) (7), synthesis of inducible and endothelial nitric oxide synthases (iNOS/eNOS) (4) and opening of mitochondrial K_{ATP} channels (3) played a crucial role in protection against I/R injury with sildenafil. More recently, we also showed that both sildenafil and vardenafil provided cardioprotection against I/R through opening of mitochondrial K_{ATP} channels when these drugs were infused at the time of reperfusion in rabbits (8).

Adenosine has been shown to be an important mediator of acute and delayed cardiac preconditioning (9,10,11). Adenosine receptor activation has been shown to protect the heart against reversible and irreversible ischemic injury in multiple species and preparations (12,13). Moreover, A₁AR knockout (A₁AR-KO) mice completely abolished the cardioprotective effect of ischemic preconditioning (14). Previous studies from our laboratory have also shown that A₁AR activation induces delayed protection through induction of iNOS (15) and opening of K_{ATP} channel (11). Considering several similarities between the signaling cascade triggered by A₁AR activation and sildenafil-induced protection, we hypothesized that the infarct limiting effect of sildenafil might be mediated via activation of A₁AR. We speculated that sildenafil pretreatment would mimic a delayed preconditioning-like effect potentially through increased A₁AR expression or augmented adenosine release from cells into the interstitial fluid which would make adenosine available to interact with its receptors, particularly during ischemia. In the current investigation, we took advantage of the A₁AR -KO mice and the selective A₁AR antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) to elucidate the direct cause-and-effect of A₁AR in inducing delayed cardioprotection in mice following treatment with sildenafil.

Materials and Methods

Animals

Adult male C57BL mice were supplied by The Jackson Laboratory (Bar Harbor, ME). The body weight for these animals ranged between 27.1 and 32.7 g. A₁AR-KO mice were obtained from a sub-colony of the original lines generated by Sun et al. (16). A₁AR-KO

mice were bred on site at the Virginia Commonwealth University School of Medicine. The deletion of A₁AR gene in the knockout mice was confirmed by RT-PCR.

Langendorff Isolated Perfused Heart Preparation

The methodology of the Langendorff isolated perfused heart has been previously described in detail (17). In brief, the mice were anesthetized with an IP injection of sodium pentobarbital (100 mg/kg containing 33 international units of heparin). The hearts were removed and submerged in ice-cold Krebs-Henseleit (K-H) solution containing heparin. The aorta was secured to a 20 gauge stainless steel blunt needle, and the hearts were perfused at a constant temperature and pressure in a retrograde fashion via the aorta with K-H solution. Following a stabilization period of 30 minutes, I/R injury was produced by subjecting the hearts to 30 minutes of normothermic, no-flow global ischemia followed by reperfusion for 60 minutes. To obtain the developed pressure, a left atrial incision was made to expose the mitral annulus through which a water-filled latex balloon was passed into the left ventricle (LV). The balloon was attached via polyethylene tubing to a Gould pressure transducer that was connected to a PowerLab Acquisition System (ADInstruments 8SP, Australia). The balloon was inflated to adjust the LV end-diastolic pressure (LVEDP) to ~ 10 mmHg. Myocardial ischemic damage was measured using multiple, independent end points of tissue injury. These included infarct size, LV developed pressure (LVDP), LVEDP, rate-pressure product (RPP), heart rate, and coronary flow by timed collection of the perfusate. LVDP was calculated by subtracting LVEDP from the peak systolic pressure. RPP, an index of cardiac work, was calculated by multiplying LVDP with heart rate. The hearts were not paced.

Study Protocol

Mice were randomly assigned into one of the following groups as shown in Figure 1:

Group I: [saline control, C57BL (WT) mice; n=6]: WT mice received 0.2 ml 0.9 % saline, *i.p.*;

Group II: (Sildenafil, WT mice; n=6): Pure sildenafil powder (kindly provided by Pfizer, Inc.) was dissolved in 0.2 ml saline. This preparation was given in WT mice as 0.71 mg/kg *i.p.* bolus, approximating, on a mg/kg basis, the clinical dose of 50 mg administered to a 70 kg patient;

Group III: (DPCPX+sildenafil, WT mice; n=6): DPCPX (0.1mg/kg) was administered 30 min prior to sildenafil treatment in WT mice as in Group II;

Group IV: (DPCPX+saline, WT mice; n=6): WT mice were treated with DPCPX (0.1mg/kg) 30 min prior to saline treatment as in Group I;

Group V: (DMSO+sildenafil, WT mice, n=6): DMSO (solvent for DPCPX) was administered in WT mice 30 min prior to sildenafil treatment as in group II;

Group VI: (DMSO+saline, WT mice, n=6): WT mice were given DMSO 30 min prior to saline treatment as in Group I;

Group VII: (Saline control, A₁AR -KO; n=6): A₁AR -KO mice received 0.2 ml 0.9% saline, *i.p.*;

Group VIII: (*Sildenafil*, A_1AR -KO; $n=6$): A_1AR -KO mice received 0.71 mg/kg sildenafil as in Group II.

Twenty-four hours later, the hearts were isolated and subjected to I/R as described above.

Isolation of Adult Mouse Ventricular Cardiomyocytes

Adult male C57BL-WT or A_1AR -KO mice were used in this study. The ventricular cardiomyocytes were isolated using an enzymatic technique modified from the previously reported method (18,19). In brief, the animal was anesthetized with pentobarbital sodium (100 mg/kg, i.p.) and the heart was quickly removed. Within 3 min, the aortic opening was cannulated onto a Langendorff perfusion system and the heart was retrogradely perfused (37°C) at a constant pressure of 55 mmHg for ~5 min with a Ca^{2+} -free bicarbonate-based buffer containing (in mM): 120 NaCl, 5.4 KCl, 1.2 $MgSO_4$, 1.2 NaH_2PO_4 , 5.6 glucose, 20 $NaHCO_3$, 10 2,3-butanedione monoxime, and 5 taurine, which was continuously bubbled with 95% O_2 + 5% CO_2 . The enzymatic digestion was commenced by adding collagenase type II (Worthington, 0.5 mg/mL each) and protease type XIV (0.02 mg/mL) to the perfusion buffer and continued for ~15 min. 50 μM Ca^{2+} was then added in to the enzyme solution for perfusing the heart for another 10-15 min. The digested ventricular tissue was cut into chunks and gently aspirated with a transfer pipette for facilitating the cell dissociation. The cell pellet was resuspended for a 3-step Ca^{2+} restoration procedure (*i.e.* 125, 250, 500 μM Ca^{2+}). The freshly isolated cardiomyocytes were then suspended in minimal essential medium (Sigma catalogue# 6 M1018, pH 7.35-7.45) containing 1.2 mM Ca^{2+} , 12 mM $NaHCO_3$, 2.5% fetal bovine serum and 1% penicillin-streptomycin. The cells were then plated onto the 35 mm cell culture dishes, which were pre-coated with 20 $\mu g/mL$ mouse laminin in PBS + 1% penicillin-streptomycin for 1 hour. The cardiomyocytes were cultured in the presence of 5% CO_2 for 1 hour in a humidified incubator at 37°C, which allowed cardiomyocytes to attach to the dish surface prior to the experimental protocol.

Experimental Protocol

The cultured cardiomyocytes were incubated under 37°C and 5% CO_2 , for 1 hour with or without 1 μM sildenafil powder dissolved in distilled water. The drug solution was filtered (0.45 μm pore size) before adding into the cell medium. Cardiomyocytes were subjected to simulated ischemia (SI) for 40 minutes by replacing the cell medium with an “ischemia buffer” which contained (in mM): 118 NaCl, 24 $NaHCO_3$, 1.0 NaH_2PO_4 , 2.5 $CaCl_2 \cdot 2H_2O$, 1.2 $MgCl_2$, 20 sodium lactate, 16 KCl, 10 2-deoxyglucose (pH adjusted to 6.2). In addition, the cells were incubated under hypoxic conditions at 37°C during the entire SI period by adjusting the tri-gas incubator to 1-2% O_2 and 5% CO_2 . Reoxygenation (RO) was accomplished by replacing the ischemic buffer with normal medium under normoxic conditions. Assessment of cell necrosis was performed after 1 hour of RO.

Evaluation of Cell Viability

Cell viability was assessed by trypan blue exclusion assay. At the end of protocol, 20 μL of 0.4% trypan blue (Sigma-Aldrich) was added into the culture dish. After ~5 min of equilibration, the cells were counted under microscope.

Statistics

All measurements are expressed as means $\pm$ SE. The data were analyzed by either unpaired *t*-test or one-way ANOVA. If a significant value of *F* was obtained in ANOVA, the Student-Newman-Keuls post hoc test was further used for pair wise comparisons. Paired *t*-test was used to compare any pair of pre- and post-treatment values for the same parameter. *P* < 0.05 was considered significant.

Results

Left ventricular cardiac function

There was no significant difference in the basal functional parameters (*i.e.* heart rate, LVDP and LVEDP) between the groups after 20 min stabilization (Table 1). Except in the A₁AR-KO mice treated with saline, no significant changes in the rate pressure product were observed during post-ischemia (Figure 2) between the groups. Post-ischemic coronary flow was also not significantly different among the groups as shown in Table 2.

Myocardial Infarction

Following I/R, myocardial infarct size (Mean $\pm$ SEM; % of risk area) was reduced in wild-type mice treated with sildenafil (5.6 $\pm$ 0.9) versus saline group (27.3 $\pm$ 2.1; *P*<0.05; *n*=6/each; Figure 3). In contrast, sildenafil failed to reduce infarct size in the A₁AR-KO mice (31.6 $\pm$ 1.9 vs. 32.3 $\pm$ 1.5 with saline, *p*>0.05). Moreover, the selective A₁AR antagonist DPCPX blocked the infarct-limiting effect of sildenafil in the wild-type mice (27.3 $\pm$ 3.2, *p*<0.05). There was no significant difference in the infarct size between controls and animals treated with DPCPX or DMSO, the solvent for DPCPX.

Effect of Sildenafil on Cardiomyocyte Necrosis

Our method for cell preparations yielded at least 70% of the cardiomyocytes with rod shape morphology, which was similar to the previously reported study from our laboratory and others (18,19). After 40 min of SI and 1 hour of RO, the percent of trypan blue positive cardiomyocytes were 53 $\pm$ 2.8, (control). Pretreatment with sildenafil for 1 hr resulted in the ~54 % decrease in trypan blue positive cardiomyocytes *i.e.*, 24.5 $\pm$ 2.6 % *p*<0.05, vs control *n*=3; Figure 4). The A₁AR selective antagonist, DPCPX, abolished the protective effect of sildenafil as shown by increase in the trypan blue positive cells (50.8 $\pm$ 3.0; *P*>0.05 vs. control). DPCPX or its solvent DMSO alone had no effect on trypan blue positive cell count. Furthermore, cardiomyocytes derived from A₁AR-KO mice failed to show protection against SI/RO when treated with sildenafil (46.7 $\pm$ 2.3 % vs. 51.9 $\pm$ 4.4 non-treated control A₁AR-KO cardiomyocytes; *P*>0.05).

Discussion

The major goal of this study was to test the hypothesis whether A₁AR plays an obligatory role in protection against I/R injury with sildenafil in the intact heart and cardiomyocytes. As previously shown in the ICR mice also (4), sildenafil caused an impressive reduction of infarct size in hearts isolated from C57BL-WT mice. The protection was abolished by both selective A₁AR antagonist DPCPX as well as genetic deletion of A₁AR. Similar results were

obtained in an independent acute model of primary adult murine cardiomyocytes that were subjected to SI/RO *in vitro*. The number of trypan blue positive necrotic cells following SI/RO was significantly lower in the sildenafil-treated group as compared with the saline-treated control cardiomyocytes. Also, sildenafil-induced protection against SI/RO was abolished by DPCPX in the wild type cardiomyocytes or in cardiomyocytes isolated from A₁AR-KO mice. Taken together, these combinatorial approaches of pharmacologic inhibition and gene knockout along with the use of *in vitro* and intact organ model provide conclusive evidence that activation of A₁AR plays an essential role in sildenafil induced protection in the heart.

Adenosine is a ubiquitous biological compound formed as a consequence of the breakdown of ATP during ischemic preconditioning. The adenosine receptor system is an intrinsic mechanism which has role in modifying cell death and injury, inflammatory processes, and cardiac and vascular remodeling during/after ischemic or hypoxic insult and also protect the heart against the injury of I/R and inflammation (Reviewed in 20). It has been shown that inhibition of A₁AR activation prevents protection with ischemic preconditioning in rabbits (9), dogs (21), and isolated human right atrial trabeculae (22). Moreover, A₁AR deletion prevents protection against myocardial infarction *in vivo* following ischemic preconditioning in mice (23). Activation of A₁ARs has been shown to protect the heart from I/R-induced stunning as well as infarction (24,25). Moreover, cardiac-selective A₁AR overexpression demonstrated enhanced ischemic tolerance as evidenced by reduction of infarction and improved recovery of contractile function (26). Conversely, A₁AR-KO mice were shown to have diminished recovery of left ventricular function compared with WT controls (27). In the present study, we observed that treatment with sildenafil failed to reduce infarct size in the A₁AR-KO as compared to the WT controls. These observations were further supported by the ability of DPCPX to block the infarct limiting effect of sildenafil in the WT control hearts. Similar results were obtained when these experiments were reproduced in adult cardiomyocytes subjected to simulated ischemia/reoxygenation. Schulte et al. (28) reported abrogation of the infarct sparing effect of remote (cerebral) ischemic preconditioning in A₁AR-KO hearts while postischemic functional tolerance was not altered by A₁AR deletion. It is well known that extracellular adenosine acts via four known G-protein-coupled receptor (GPCR) sub-types including A₁, A_{2A}, A_{2B}, and A₃ receptors (30). Adenosine A₁ and A₃ receptors inhibit adenylyl cyclase and stimulate phospholipase C via activation of pertussis toxin sensitive G proteins G_i and /or G_o. A_{2A} and A_{2B} are positively coupled to adenylyl cyclase but also activate alternate signaling pathways (31,32). However, it is unlikely that the lack of protective effect of sildenafil in the A₁AR-KO mice is due to compensatory changes in the expression of other receptor subtypes because A_{2A}, A_{2B}, or A₃ receptors were not altered in A₁AR-KO compared with WT hearts (27).

Our data raise the intriguing possibility that sildenafil may have caused enhanced expression of A₁AR on cardiomyocytes, particularly 24 hrs after treatment. In support of this notion, recent studies have demonstrated that exogenously generated NO as well lipopolysaccharide (LPS) increased A₁AR expression in pheochromocytoma 12 cells and in primary cultures of cortical neurons (29). With LPS, the A₁AR expression was dependent on the induction of

inducible nitric oxide synthase (iNOS) because inhibition of NOS activity suppressed this response in these studies. It appears that sildenafil might have worked through NO-dependent increased A₁AR expression. This is because sildenafil is known to cause rapid induction of eNOS and iNOS mRNA and significant increase in cardiac expression of the proteins within 24 hours of treatment in the heart (4). However, considering the shorter duration of action of DPCPX (approximately 5 hrs) in antagonizing the actions of adenosine (33), it is not clear how this compound would have been able to block the protective effect of upregulated A₁AR 24 hrs later. It is possible that such an action of DPCPX may be indicative of a lack of specificity of action. Alternatively, sildenafil may have caused enhanced release of adenosine through generation of NO which would have activated the A₁AR receptor and led to subsequent protection from I/R injury 24 hrs later. Additional studies are needed to address this hypothesis.

In summary, for the first time, we have shown that sildenafil induces delayed cardioprotective effects against myocardial I/R injury through selective activation of A₁AR. Considering the similarity of action of other PDE-5 inhibitors including Vardenafil and Tadalafil, it is possible that these drugs may also require A₁AR activation for protecting the heart against I/R. We therefore propose that the class of PDE-5 inhibitors including sildenafil could be a novel strategy to selectively activate A₁AR function for protection of the heart against myocardial infarction following I/R injury and remodeling.

Acknowledgments

This study was supported in part by grants from National Institutes of Health HL51045, HL59469, and HL79424 to RCK. We thank Dr. J Schnermann of National Institute of Diabetes, and Digestive and Kidney Diseases, NIH, Bethesda, MD for supplying A₁ receptor knockout mice.

References

1. Kukreja RC, Salloum FN, Xi L. Nonurologic Applications of Phosphodiesterase Type 5 Inhibitors. *Current Sexual Health Reports*. 2007; 4:64–70.
2. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. *N Engl J Med*. 2005; 353(20):2148–57. [PubMed: 16291984]
3. Ockaili R, Salloum F, Hawkins J, Kukreja RC. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. *Am J Physiol Heart Circ Physiol*. 2002; 283:H1263–9. [PubMed: 12181158]
4. Salloum F, Yin C, Xi L, Kukreja RC. Sildenafil induces delayed preconditioning through iNOS-dependent pathway in mouse Heart. *Circulation Research*. 2003; 92:595–597. [PubMed: 12637371]
5. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditioning protects adult cardiac myocytes against necrosis and apoptosis: Essential role of NO signaling. *J Biol Chem*. 2005; 280:12944–55. [PubMed: 15668244]
6. Das A, Ockaili R, Salloum F, Kukreja RC. Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits. *Am J Physiol Heart Circ Physiol*. 2003; 286(4):H1455–60. [PubMed: 15020304]
7. Salloum F, Xi L, Ockaili R, Yin C, Kukreja RC. Delayed pharmacological preconditioning with Viagra (Sildenafil) against myocardial infarction is independent of p38 MAPK signaling pathway. *Circulation*. 2002; 106(19):1880. Suppl. S II-378 (Abstract).
8. Salloum FN, Takenoshita Y, Ockaili RA, Daoud VP, Chou E, Yoshida K, Kukreja RC. Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial

- K_{ATP} channels when administered at reperfusion following ischemia in rabbits. *J Mol Cell Cardiol.* 2007; 42(2):453–8. [PubMed: 17157308]
9. Liu GS, Thornton JD, Van Winkle DM, Stanley AWH, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A₁ adenosine receptors in rabbit heart. *Circulation.* 1991; 84:350–356. [PubMed: 2060105]
 10. Baxter GF, Marber MS, Patel VC, Yellon DM. Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning. *Circulation.* 1994; 90:2993–3000. [PubMed: 7994847]
 11. Bernardo NL, Okubo S, Maaieh M, Wood M, Kukreja RC. Delayed preconditioning with adenosine is mediated by opening of ATP-sensitive K⁺ channel in rabbit heart. *Am J Physiol.* 1999; 277:H128–H135. [PubMed: 10409190]
 12. Lasley RD, Narayan P, Mentzer RM Jr. New Insights into adenosine receptor modulation of myocardial ischemia-reperfusion injury. *Drug Develop Res.* 2001; 52:357–365.
 13. Mubagwa K, Fameng W. Adenosine, adenosine receptors and myocardial protection: an updated overview. *Cardiovasc Res.* 2001; 52:25–39. [PubMed: 11557231]
 14. Reichelt ME, Willems L, Molina JG, Sun CX, Noble JC, Ashton KJ, Schnermann J, Blackburn MR, Headrick JP. Genetic deletion of the A₁ adenosine receptor limits myocardial ischemic tolerance. *Circ Res.* 2005; 96(3):363–7. [PubMed: 15653569]
 15. Zhao T, Xi L, Chelliah J, Levasseur JE, Kukreja RC. Inducible nitric oxide synthase mediates delayed protection induced by activation of adenosine A₁ receptors: evidence from gene knockout mice. *Circulation.* 2000; 102:902–907. [PubMed: 10952960]
 16. Sun D, Samuelson LC, Yang T, Huang Y, Paliege A, Saunders T, Briggs J, Schnermann J. Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. *Proc Natl Acad Sci USA.* 2001; 98:9983–9988. [PubMed: 11504952]
 17. Xi L, Jarrett NC, Hess ML, et al. Essential role of inducible nitric oxide synthase in monophosphoryl lipid A-induced late cardioprotection: evidence from pharmacological inhibition and gene knockout mice. *Circulation.* 1999; 99:2157–2163. [PubMed: 10217657]
 18. Xiao RP, Avdonin P, Zhou YY, Cheng H, Akhter SA, Eschenhagen T, Lefkowitz RJ, Koch WJ, Lakatta EG. Coupling of beta₂-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. *Circ. Res.* 1999; 84:43–52. [PubMed: 9915773]
 19. Zhou YY, Wang SQ, Zhu W, Chruscinski A, Kobilka B, Ziman B, Wang S, Lakatta EG, Cheng H, Xiao RP. Culture and adenoviral infection of adult mouse cardiac myocytes: methods for cellular genetic physiology. *Am. J. Physiol. Heart Circ. Physiol.* 2000; 279:H429–H436. [PubMed: 10899083]
 20. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. *Cell Death Differ.* 2007; 14:1315–23. [PubMed: 17396131]
 21. Auchampach JA, Gross GJ. Adenosine A₁ receptors, K_{ATP} channels, and ischemic preconditioning in dogs. *Am J Physiol Heart Circ Physiol.* 1993; 264:H1327–H1336.
 22. Walker DM, Walker JM, Pugsley WB, Pattison CW, Yellon DM. Preconditioning in isolated superfused human muscle. *J Mol Cell Cardiol.* 1995; 27:1349–1357. [PubMed: 8531217]
 23. Lankford AR, Yang JN, Rose-Meyer R, French BA, Matherne GP, Fredholm BB, Yang Z. Effect of modulating cardiac A₁ adenosine receptor expression on protection with ischemic preconditioning. *Am J Physiol Heart Circ Physiol.* 2006; 290:H1469–H1473. [PubMed: 16299262]
 24. Cleveland JC, Meldrum DR, Rowland RT, Banerjee A, Harken AH. Adenosine preconditioning of human myocardium is dependent upon the ATP-sensitive K⁺ channel. *J Mol Cell Cardiol.* 1997; 29:175–182. [PubMed: 9040032]
 25. Lasley RD, Rhee JW, Van Wylen DGL, Mentzer RM. Adenosine A₁ receptor mediated protection of the globally ischemic isolated rat heart. *J Mol Cell Cardiol.* 1990; 22:39–47. [PubMed: 2325132]
 26. Matherne GP, Linden J, Byford AM, Gauthier NS, Headrick J. Transgenic A₁ adenosine receptor overexpression increases myocardial resistance to ischemia. 1997; 94:6541–6546.
 27. Morrison RR, Teng B, Oldenburg PJ, Katwa LC, Schnermann JB, Mustafa SJ. Effects of targeted deletion of A₁ adenosine receptors on postischemic cardiac function and expression of adenosine

- receptor subtypes. *Am J Physiol Heart Circ Physiol*. Oct. 2006; 291(4):H1875–82. [PubMed: 16679400]
28. Schulte G, Sommerschild H, Yang J, Tokuno S, Gojny M, Lovdahl C, Johansson B, Fredholm BB, Valen G. Adenosine A₁ receptors are necessary for protection of the murine heart by remote delayed adaptation to ischaemia. *Acta Physiol Scand*. 2004; 182:133–143. [PubMed: 15450109]
29. Jhaveri KA, Toth LA, Sekino Y, Ramkumar V. Nitric oxide serves as an endogenous regulator of neuronal adenosine A₁ receptor expression. *J Neurochem*. 2006; 99(1):42–53. [PubMed: 16987234]
30. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacol. Rev.* 2001; 53:527–552. [PubMed: 11734617]
31. Feoktistov I, Biaggioni I. Positive modulation of intracellular Ca²⁺ levels by adenosine A_{2b} receptors, prostacyclin, and prostaglandin E₁ via a cholera toxin-sensitive mechanism in human erythroleukemia cells. *Mol Pharmacol*. 1994; 45:1160–1167. [PubMed: 8022409]
32. Feoktistov I, Biaggioni I. Adenosine A_{2b} receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. *J Clin Inv*. 1995; 96:1979–1986.
33. Knight RJ, Collins MG, Yates MS, Bowmer CJ. Ameriolation of cisplatin-induced acute renal failure with 8-cyclopentyl-1,3-dipropylxanthine. *Br J Pharmacol Exp Ther*. 1992; 263:657–662.

Experimental Protocol

Figure 1.
Experimental protocol showing various groups.

Figure 2.

Effect of sildenafil, DPCPX, and genetic deletion of A₁AR on ventricular functional recovery following global ischemia-reperfusion.

Figure 3.

TOP: Representative sections of the heart showing infarction (white) with 10% TTC staining. More viable tissue (red) is prominent in the sildenafil-treated WT mice as compared to the A₁AR -KO mice and DPCPX-treated mice.

BOTTOM: Effect of sildenafil on myocardial infarct size: role of A₁AR. Isolated perfused hearts were subjected to 30 min global ischemia and 1hr reperfusion in Langendorff mode. Values are means $\pm$ SE ($n = 6$ heart samples per group). Group II (WT) and VIII (A₁AR-KO) received sildenafil (0.71 mg/kg, ip). Group III received DPCPX (0.1 mg/kg) 30 min

before sildenafil treatment. Group (I, VII) and (IV) served as controls for sildenafil and DPCPX, respectively. $*P < 0.05$ vs. all other groups.

Figure 4.

Quantitative data showing the effect of sildenafil on myocyte viability following SI-RO: The experimental groups are same as described in the legend of Figure 3. Note that sildenafil treated control group had significantly lower % of trypan blue positive cells as compared to non-treated WT controls, sildenafil+A₁AR-KO and sildenafil+DPCPX treated groups. The percent of necrotic cardiomyocytes in DPCPX treated WT or untreated A₁AR-KO groups were not significantly different compared with the untreated control WT cardiomyocytes.

Table 1

Baseline cardiac functional parameters.

Group	WT Control	WT Sild	DPCPX+Sild	DPCPX+Saline	DMSO+Sild	DMSO+Saline	A1AR-KO+Saline	A1AR-KO+Sild
HR bpm	404±5	403±5	395±5	408±7	391±4	399±3	414±5	410±6
LVEDP mmHG	7.5±0.6	8.1±0.4	7.1±0.4	7.7±0.4	7.7±0.5	7.5±0.5	7.1±0.6	7.4±0.5
LVDP mmHg	97.8±3.1 ^{a,b}	110.3±4.0	97.7±2.9 ^{a,b}	96.6±4.5 ^{a,b}	107±3.1	102.4±2.5	115.6±3.6	114.8±2.9

Values are means±SEM. HR-Heart Rate (beats/min); LVEDP-Left Ventricular End-Diastolic Pressure (mmHg); LVDP-Left Ventricular Developed Pressure (mmHg)

^aP<0.05 vs. A1AR-KO+Saline

^bP<0.05 vs. A1AR-KO+Sildenafil

Table 2

Pre-ischemia and Reperfusion Coronary Flow Rates in the various groups.

Groups	<u>Pre-Ischemia ml/min</u>	<u>Reperfusion ml/min</u>
WT+Saline	2.1±0.4	2.4±0.4
WT+SIL	2.2±0.3	2.4±0.3
WT+DPCPX+SIL	2.4±0.7	2.8±0.6
WT+DPCPX+Saline	2.2±0.2	2.2±0.3
WT+DMSO+SIL	1.9±0.4	2.2±0.4
WT+DMSO+Saline	2.5±0.3	2.7±0.2
A1AR-KO+Saline	1.9±0.2	2.0±0.2
A1AR-KO+SIL	2.7±0.1	2.9±0.1